Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
Arbekacin (ABK) was approved and widely used in Japan for treatment of patients infected with MRSA, and TDM was introduced in clinical practice. The Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring decided to develop a clinical practice guidelines for TDM of ABK for the following reasons. First, although the daily dose of 150-200 mg was approved in Japan, recent PK-PD studies revealed that higher serum concentration is required to achieve better clinical efficacy and several findings concerning the usefulness of higher dosage regimen have obtained recently. Second, although maximal concentrations that obtained immediately after the end of administration (Cmax) was generally adopted, the serum concentration at 1 h after initiation of administration [peak serum concentration (Cpeak)] proved to be more suitable as an efficacy indicator of aminoglycosides. Lastly, as ABK is approved only in Japan, no international practice guideline for TDM has not been available in ABK to date. This guideline evaluated the scientific data associated with serum ABK monitoring and provided recommendations based on the available evidence. Potential limitations of this guideline, however, include the findings that few prospective clinical trials of TDM of ABK are available in the treatment of MRSA infections and that most of the published literature describes observational studies.
Department of Pharmacy, Tokyo Women's Medical University Hospital, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan.
Kenji
K
Okada
Department of Pharmacy, Tokyo Women's Medical University Hospital, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan.
Toshimi
T
Kimura
Department of Infection Control and Prevention, Aichi Medical University, Graduate School of Medicine, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan.
Hiroshige
H
Mikamo
Center for Infectious Diseases, Nara Medical University, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan.
Kei
K
Kasahara
Division of Infection Control and Prevention, Osaka University Medical Hospital, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan.
Masafumi
M
Seki
Department of Infection Control and Prevention, Kyoto University Hospital, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan.
Shunji
S
Takakura
Internal Medicine II, Oita University Faculty of Medicine, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan.
Issei
I
Tokimatsu
Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan.
Norio
N
Ohmagari
Department of Pharmacy, Hyogo Medical College Hospital, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan.
Yoshiko
Y
Takahashi
Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan.
Kazuaki
K
Matsumoto
Department of Pharmacy, Toranomon Hospital, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan.
Masahiro
M
Igarashi
Department of Pharmacy, Kitasato University Hospital, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan.
Masahiro
M
Kobayashi
Department of Infection Control and Prevention, Aichi Medical University, Graduate School of Medicine, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan.
Yukihiro
Y
Hamada
Department of Pharmacy, Shizuoka Cancer Center, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan.
Takahiro
T
Mochizuki
Department of Pharmacy, Aichi Medical University Hospital, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan.
Masao
M
Kimura
Department of Pharmacy, Kyorin University School of Medicine, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan.
Yoshifumi
Y
Nishi
Keio University, School of Medicine, Department of Clinical Pharmacokinetics and Pharmacodynamics, Japan; Sectional Committee of Practice Guidelines for TDM; Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Japan.
Yusuke
Y
Tanigawara
Department of Infection Control and Prevention, Hyogo Medical College Hospital, Japan; Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Japan. Electronic address: karyo@jc4.so-net.ne.jp.
Yoshio
Y
Takesue
D000890:Anti-Infective Agents / Q000592:standards* / Q000627:therapeutic use*; D032921:Consensus; D003982:Dibekacin / Q000031:analogs & derivatives* / Q000592:standards / Q000627:therapeutic use; D016903:Drug Monitoring / Q000592:standards*; D006801:Humans; D007564:Japan; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D013203:Staphylococcal Infections / Q000188:drug therapy*
D000890:Anti-Infective Agents; D003982:Dibekacin; C031986:arbekacin
Arbekacin; Guideline; MRSA; Therapeutic drug monitoring